Division of Diabetes and Endocrinology, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan,
Pituitary. 2015 Apr;18(2):274-8. doi: 10.1007/s11102-015-0637-6.
Cushing's disease (CD) is caused by adrenocorticotropic hormone (ACTH)-producing pituitary adenomas (ACTHomas). Drug treatment for CD consists of three strategies: pituitary tumor-targeted therapy, steroidogenesis inhibitors, and glucocorticoid receptor antagonists. All of these strategies are under development, and several new drugs have recently been approved for clinical use or are being tested in clinical trials. Pituitary-targeted drugs are a particularly important method in the treatment of CD. Available pituitary tumor-targeted drugs include a dopamine receptor agonist and a somatostatin analog. Since disrupted cell cycle signaling is clearly associated with pathogenesis of ACTHomas which express active forms of epithelial growth factor receptor (EGFR), cyclins, and the catalytic subunit of cyclin-dependent kinases (CDKs), we focused on these molecules as therapeutic targets for ACTHomas.
In this review, a literature search were performed using PubMed with following terms; Cushing's disease, EGFR, CDKs, cell cycle, and targeted therapy.
Accumulating evidence demonstrates that EGFR and cyclin E-CDK2 may be promising targets for treating ACTHomas.
库欣病（CD）是由促肾上腺皮质激素（ACTH）分泌性垂体腺瘤（ACTHomas）引起的。CD 的药物治疗包括三种策略：垂体瘤靶向治疗、类固醇生成抑制剂和糖皮质激素受体拮抗剂。所有这些策略都在开发中，最近有几种新药已被批准用于临床使用或正在临床试验中进行测试。针对垂体的药物是治疗 CD 的一种特别重要的方法。现有的垂体瘤靶向药物包括多巴胺受体激动剂和生长抑素类似物。由于细胞周期信号通路的紊乱与表达活性表皮生长因子受体（EGFR）、细胞周期蛋白和周期蛋白依赖性激酶（CDKs）的催化亚基的 ACTHomas 的发病机制明显相关，因此我们将这些分子作为 ACTHomas 的治疗靶点。
本文通过使用 PubMed 进行文献检索，使用以下术语：库欣病、EGFR、CDKs、细胞周期和靶向治疗。
越来越多的证据表明，EGFR 和细胞周期蛋白 E-CDK2 可能是治疗 ACTHomas 的有前途的靶点。
